Press Releases
Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia
Oct 01, 2020
Imago BioSciences to Participate in Upcoming Investor Conferences
Sep 08, 2020
Imago BioSciences Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis
Jul 30, 2020
Imago BioSciences Provides Update on Preliminary Data for Bomedemstat at the 2020 Virtual EHA Meeting
Jun 12, 2020
Imago BioSciences To Present Update on Phase 2 results of Bomedemstat (IMG-7289), a Lysine Specific Demethylase-1 (LSD1) Inhibitor for the Treatment of Myelofibrosis (MF)
May 26, 2020
Displaying 26 - 30 of 46